

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in acute promyelocytic leukaemia | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/6-1273/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/6-1273" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in acute promyelocytic leukaemia" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in acute promyelocytic leukaemia.">
            <meta name="og:description" content="Read the latest article version by Chin-Hin Ng, Wee-Joo Chng, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="11577">
            <meta name="article-id" content="10736">
            <meta name="dc.title" content="Recent advances in acute promyelocytic leukaemia">
            <meta name="dc.description" content="Acute promyelocytic leukaemia (APML) is a subtype of leukaemia arising from a distinct reciprocal translocation involving chromosomes 15 and 17, which results in the PML-RARA fusion gene. Over the past three decades, APML has been transformed from a highly fatal disease to a highly curable one. This drastic improvement is because of the introduction of a new treatment strategy with all-trans retinoic acid and, more recently, arsenic trioxide. The revolutionary treatment of APML has also paved the way for a new cancer treatment, which is genetically targeted therapy. In this review, we look into this amazing journey of transformation and provide recent advances in the management of APML.">
            <meta name="dc.subject" content="leukemia, PML, RARA, ">
            <meta name="dc.creator" content="Ng, Chin-Hin">
            <meta name="dc.creator" content="Chng, Wee-Joo">
            <meta name="dc.date" content="2017/07/28">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.10736.1">
            <meta name="dc.source" content="F1000Research 2017 6:1273">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="leukemia ">
            <meta name="prism.keyword" content=" PML ">
            <meta name="prism.keyword" content=" RARA ">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2017/07/28">
            <meta name="prism.volume" content="6">
            <meta name="prism.number" content="1273">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.10736.1">
            <meta name="prism.url" content="https://f1000research.com/articles/6-1273">
            <meta name="citation_title" content="Recent advances in acute promyelocytic leukaemia">
            <meta name="citation_abstract" content="Acute promyelocytic leukaemia (APML) is a subtype of leukaemia arising from a distinct reciprocal translocation involving chromosomes 15 and 17, which results in the PML-RARA fusion gene. Over the past three decades, APML has been transformed from a highly fatal disease to a highly curable one. This drastic improvement is because of the introduction of a new treatment strategy with all-trans retinoic acid and, more recently, arsenic trioxide. The revolutionary treatment of APML has also paved the way for a new cancer treatment, which is genetically targeted therapy. In this review, we look into this amazing journey of transformation and provide recent advances in the management of APML.">
            <meta name="citation_description" content="Acute promyelocytic leukaemia (APML) is a subtype of leukaemia arising from a distinct reciprocal translocation involving chromosomes 15 and 17, which results in the PML-RARA fusion gene. Over the past three decades, APML has been transformed from a highly fatal disease to a highly curable one. This drastic improvement is because of the introduction of a new treatment strategy with all-trans retinoic acid and, more recently, arsenic trioxide. The revolutionary treatment of APML has also paved the way for a new cancer treatment, which is genetically targeted therapy. In this review, we look into this amazing journey of transformation and provide recent advances in the management of APML.">
            <meta name="citation_keywords" content="leukemia, PML, RARA, ">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Chin-Hin Ng">
            <meta name="citation_author_institution" content="National University Cancer Institute, Singapore, Singapore">
            <meta name="citation_author" content="Wee-Joo Chng">
            <meta name="citation_author_institution" content="National University Cancer Institute, Singapore, Singapore">
            <meta name="citation_publication_date" content="2017/07/28">
            <meta name="citation_volume" content="6">
            <meta name="citation_publication_number" content="1273">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.10736.1">
            <meta name="citation_firstpage" content="1273">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/6-1273/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/6-1273.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=11577 /> <input type=hidden id=articleId name=articleId value=10736 /> <input type=hidden id=xmlUrl value="/articles/6-1273/v1/xml"/> <input type=hidden id=xmlFileName value="-6-1273-v1.xml"> <input type=hidden id=article_uuid value=9c9031e7-dd39-4e81-bd80-00e207367a11 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in acute promyelocytic leukaemia"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.10736.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.10736.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/6-1273"
  },
  "headline": "Recent advances in acute promyelocytic leukaemia",
  "datePublished": "2017-07-28T14:49:49",
  "dateModified": "2017-07-28T14:49:49",
  "author": [
    {
      "@type": "Person",
      "name": "Chin-Hin Ng"
    },    {
      "@type": "Person",
      "name": "Wee-Joo Chng"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Acute promyelocytic leukaemia (APML) is a subtype of leukaemia arising from a distinct reciprocal translocation involving chromosomes 15 and 17, which results in the PML-RARA fusion gene. Over the past three decades, APML has been transformed from a highly fatal disease to a highly curable one. This drastic improvement is because of the introduction of a new treatment strategy with all-trans retinoic acid and, more recently, arsenic trioxide. The revolutionary treatment of APML has also paved the way for a new cancer treatment, which is genetically targeted therapy. In this review, we look into this amazing journey of transformation and provide recent advances in the management of APML."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/6-1273.html",
            "name": "Recent advances in acute promyelocytic leukaemia"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in acute promyelocytic leukaemia </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=11577 data-id=10736 data-downloads="" data-views="" data-scholar="10.12688/f1000research.10736.1" data-recommended="" data-doi="10.12688/f1000research.10736.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/6-1273/v1/pdf?article_uuid=9c9031e7-dd39-4e81-bd80-00e207367a11" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-10736-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-10736-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-10736-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Ng CH and Chng WJ. Recent advances in acute promyelocytic leukaemia [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):1273 (<a class=new-orange href="https://doi.org/10.12688/f1000research.10736.1" target=_blank>https://doi.org/10.12688/f1000research.10736.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-10736-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=10736 id=track-article-signin-10736 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/10736?target=/articles/6-1273.html">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=11577 /> <input name=articleId type=hidden value=10736 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in acute promyelocytic leukaemia</h1><span class=other-info> [version 1; peer review: 3 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:chin_hin_ng@nuhs.edu.sg" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Chin-Hin Ng</span></a><a href="https://orcid.org/0000-0003-3688-7611" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-3688-7611</div>,&nbsp;</span><span class="">Wee-Joo Chng</span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:chin_hin_ng@nuhs.edu.sg" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Chin-Hin Ng</span></a><a href="http://orcid.org/0000-0003-3688-7611" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-3688-7611</div>,&nbsp;</span><span class="">Wee-Joo Chng</span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 28 Jul 2017 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.10736.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> National University Cancer Institute, Singapore, Singapore<br/> <p> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=23044-22874></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=23043-22875></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=23045-22873></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Acute promyelocytic leukaemia (APML) is a subtype of leukaemia arising from a distinct reciprocal translocation involving chromosomes 15 and 17, which results in the <i>PML-RARA</i> fusion gene. Over the past three decades, APML has been transformed from a highly fatal disease to a highly curable one. This drastic improvement is because of the introduction of a new treatment strategy with all-trans retinoic acid and, more recently, arsenic trioxide. The revolutionary treatment of APML has also paved the way for a new cancer treatment, which is genetically targeted therapy. In this review, we look into this amazing journey of transformation and provide recent advances in the management of APML. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> leukemia, PML, RARA, </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Chin-Hin Ng (<a href="mailto:chin_hin_ng@nuhs.edu.sg">chin_hin_ng@nuhs.edu.sg</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Chin-Hin Ng </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> The authors declare that they have no competing interests. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp;  2017 Ng CH and Chng WJ. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Ng CH and Chng WJ. Recent advances in acute promyelocytic leukaemia [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):1273 (<a href="https://doi.org/10.12688/f1000research.10736.1" target=_blank>https://doi.org/10.12688/f1000research.10736.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 28 Jul 2017, <b>6</b>(F1000 Faculty Rev):1273 (<a href="https://doi.org/10.12688/f1000research.10736.1" target=_blank>https://doi.org/10.12688/f1000research.10736.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 28 Jul 2017, <b>6</b>(F1000 Faculty Rev):1273 (<a href="https://doi.org/10.12688/f1000research.10736.1" target=_blank>https://doi.org/10.12688/f1000research.10736.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d28887e153>Introduction</h2><p class="" id=d28887e156>Acute myeloid leukaemia (AML) is a heterogeneous disease that results from the abnormal maturation of myeloid lineages. Based on the early French-American-British (FAB) classification, acute promyelocytic leukaemia (APML) is one of the subtypes (M3) of AML. It arises from a distinct reciprocal translocation involving chromosomes 15 and 17, which results in the <i>PML-RARA</i> fusion gene, t(15;17)(q24.1;q21.1)<sup><a href="#ref-1">1</a></sup>. A number of rarer variant translocations involving the <i>RARA</i> gene associated with APML, including t(11;17) and t(5;17), have also been identified<sup><a href="#ref-2">2</a></sup>. The disruption of the <i>RARA</i> gene results in maturation arrest of myeloid progenitors at the promyelocytic stage, and treatment with all-trans retinoic acid (ATRA) was able to induce differentiation in <i>in vitro</i> and <i>in vivo</i> models<sup><a href="#ref-3">3</a></sup> and induce complete remission (CR) in patients with APML, though with short duration of CR as monotherapy<sup><a href="#ref-4">4</a></sup>. Subsequent incorporation of ATRA into standard chemotherapy (CT) in many studies and, more recently, the introduction of arsenic trioxide (ATO) into the treatment strategy demonstrated dramatic improvement in clinical outcomes, transforming a previously deadly disease into a highly curable one<sup><a href="#ref-5">5</a></sup>. However, a few issues remain unsettled; these include the long-term safety profile and efficacy of ATO, the need for maintenance therapy in the era of ATRA/ATO, and the effectiveness of differentiation syndrome (DS) prophylaxis to name a few.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d28887e198>Variant translocation in acute promyelocytic leukaemia</h2><p class="" id=d28887e201>Translocation involving <i>PML</i> and <i>RARA</i> genes, accounting for more than 90% of cases, is by far the most common fusion partner in APML. Other fusion partners include <i>PZLF-RARA</i><sup><a href="#ref-6">6</a></sup>, <i>NPM-RARA</i><sup><a href="#ref-7">7</a></sup>, <i>NuMA-RARA</i><sup><a href="#ref-8">8</a></sup>, and the more recently discovered <i>STAT5b-RARA</i><sup><a href="#ref-9">9</a></sup> and <i>BCOR-RARA</i><sup><a href="#ref-10">10</a></sup>. These rarer fusion genes account for around 5% of the total. The clinical significance of these variant fusion genes is their response to ATRA. <i>PZLF-RARA</i> and <i>STAT5b-RARA</i> cases were refractory to ATRA, whereas <i>NPM-RARA</i> and <i>NuMA-RARA</i> were reported to be responsive. <i>BCOR-RARA</i> was also responsive to ATRA but carries a higher risk of relapse<sup><a href="#ref-10">10</a>,<a href="#ref-11">11</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d28887e266><i>FLT3-</i>ITD in acute promyelocytic leukaemia</h2><p class="" id=d28887e271>FMS-like tyrosine kinase 3 (FLT3) is a transmembrane tyrosine kinase receptor that is involved in cell proliferation. Mutation in the <i>FLT3</i> gene that results in internal tandem duplication (ITD) and constitutively active tyrosine kinase receptor is relatively common in AML, especially in those with a normal karyotype. AML with <i>FLT3</i>-ITD is associated with a high risk of relapse and generally is considered to be a high-risk disease requiring allogeneic stem cell transplantation. However, the clinical impact of <i>FLT3</i>-ITD in APML is still controversial.</p><p class="" id=d28887e283>The incidence of <i>FLT3</i>-ITD in APML is 20 to 30%<sup><a href="#ref-12">12</a>,<a href="#ref-13">13</a></sup>. According to the International Consortium on APML Study, <i>FLT3</i>-ITD was associated with a significantly higher presenting white blood cell (WBC) count and hence with high-risk groups. With a median follow-up of 38 months, <i>FLT3</i>-ITD APML showed an inferior overall survival (OS) at 3 years (62% versus 82%). In the multivariate analysis that included age, presenting WBC count, albumin, and <i>FLT3</i>-ITD status, <i>FLT3</i>-ITD-positive APML was independently associated with inferior OS. However, the cut-off used for the WBC count was 50  10<sup>9</sup>/L instead of the more widely used 10  10<sup>9</sup>/L<sup><a href="#ref-12">12</a></sup>. In a separate study involving 245 APML cases, <i>FLT3</i>-ITD status did not seem to affect clinical outcomes, especially in those patients who received ATO<sup><a href="#ref-13">13</a></sup>. Similarly, in an Italian series of 159 APML cases, <i>FLT3</i>-ITD-positive APML had no significant impact on either event-free survival (EFS) or cumulative incidence of relapse in patients receiving ATRA-ATO. However, there was a trend towards inferior EFS in <i>FLT3</i>-ITD cases receiving the ATRA plus CT (ATRA-CT) regimen<sup><a href="#ref-14">14</a></sup>.</p><p class="" id=d28887e336>A meta-analysis involving 11 studies and 1,063 patients, who mostly received the ATRA-CT regimen, showed an inferior OS and disease-free survival (DFS) in <i>FLT3</i>-ITD-positive APML<sup><a href="#ref-15">15</a></sup>.</p><p class="" id=d28887e346>The clinical impact of <i>FLT3</i>-ITD is likely muddled by the concurrent high WBC count, which is the most important risk factor in APML. Hence, the role of <i>FLT3</i>-ITD in further risk stratification of the currently available method is likely redundant (<a href="#T1">Table 1</a>). The prognostic impact of <i>FLT3</i>-ITD in the era of ATRA-ATO upfront treatment might not be significant after all. Furthermore, the use of an FLT3 inhibitor in APML has yet to be established. Routine checking of <i>FLT3</i>-ITD status is probably unwarranted.</p><div class="table-wrap panel clearfix"><a name=T1 class=n-a></a><div class=caption><h3>Table 1. Risk stratification in acute promyelocytic leukaemia<sup><a href="#ref-67">67</a></sup>.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d28887e380 class=n-a></a><thead><a name=d28887e382 class=n-a></a><tr><a name=d28887e384 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d28887e386 class=n-a></a>Risk</th><th align=left colspan=1 rowspan=1 valign=top><a name=d28887e389 class=n-a></a>White blood<br class=br>cells,  10<sup>9</sup>/L</th><th align=left colspan=1 rowspan=1 valign=top><a name=d28887e397 class=n-a></a>Platelets,<br class=br> 10<sup>9</sup>/L</th><th align=left colspan=1 rowspan=1 valign=top><a name=d28887e405 class=n-a></a>Three-year relapse-<br class=br>free survival</th></tr></thead><tbody><a name=d28887e412 class=n-a></a><tr><a name=d28887e414 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e416 class=n-a></a>Low</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e419 class=n-a></a>&lt;10</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e422 class=n-a></a>&gt;40</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e425 class=n-a></a>98%</td></tr><tr><a name=d28887e429 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e431 class=n-a></a>Intermediate</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e434 class=n-a></a>&lt;10</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e437 class=n-a></a>&lt;40</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e440 class=n-a></a>89%</td></tr><tr><a name=d28887e444 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e446 class=n-a></a>High</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e449 class=n-a></a>&gt;10</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e452 class=n-a></a>-</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e455 class=n-a></a>70%</td></tr></tbody></table></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d28887e465>Other prognostic factors</h2><p class="" id=d28887e468>In a recent review by Testa and Lo-Coco, immunophenotypes in APML might play some roles in prognostication and are associated with characteristic clinical phenotypes<sup><a href="#ref-16">16</a></sup>. CD56 is over-expressed in about 10% of APML and often is associated with high WBC count<sup><a href="#ref-14">14</a></sup>. Its expression is associated with increased relapse risk and inferior relapse-free survival (RFS), EFS, and OS in a number of studies<sup><a href="#ref-17">17</a><a href="#ref-19">19</a></sup>. CD2 expression was also found in around 24% of APML cases and was associated with CD34 positivity, higher WBC count, and microgranular subtype<sup><a href="#ref-20">20</a>,<a href="#ref-21">21</a></sup>. In a separate series of 132 Chinese patients with APML, CD2 expression was found to be associated with early death. However, in the multivariate analysis involving CD2, CD34, CD56, and WBC count, only increased WBC count was an independent prognostic factor for early death and OS<sup><a href="#ref-22">22</a></sup>. In an analysis of 114 APML cases, Breccia <i>et al.</i> observed that the CD34/CD2-positive subgroup displayed several differential propertiesincluding higher frequencies of M3v (27% versus 7%), bcr3 transcript subtype (73% versus 32%), higher incidence of DS (26% versus 12%), higher rate of relapse (66% versus 17%), and lower OS (88% versus 95%)compared with CD34-negative patients<sup><a href="#ref-23">23</a></sup>.</p><p class="" id=d28887e505>Additional mutations are not uncommon in APML, particularly in the high-risk group. Patients with mutations of the epigenetic modifier genes were reported to have a significantly reduced OS and RFS compared with patients lacking these mutations<sup><a href="#ref-24">24</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d28887e515>Additional chromosomal abnormalities in acute promyelocytic leukaemia</h2><p class="" id=d28887e518>In a large UK Medical Research Council (MRC) trial with more than 5,000 patients with AML, the cytogenetics of 607 patients with APML were further analysed to elucidate the clinical impact of additional chromosomal abnormalities<sup><a href="#ref-25">25</a></sup>. The patients with APML received ATRA and anthracycline-based CT, and the presence of additional chromosomal abnormalities did not affect the clinical outcomes. This included patients with 17p or other adverse karyotypes known to confer poor outcome in AML.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d28887e529>Mutational landscape in acute promyelocytic leukaemia</h2><p class="" id=d28887e532>In a recently published study on the mutational analysis of APML by Madan <i>et al.</i> from the Cancer Science Institute of Singapore, a comprehensive mutational landscape of primary and relapsed APML was unveiled<sup><a href="#ref-26">26</a></sup>; 153 primary and 69 relapsed APML samples were explored by using whole-genome sequencing (n = 12) and subsequent targeted sequencing of 368 genes. <i>FLT3</i> emerged as the most frequently altered gene in primary APML samples. This included 27% of cases with <i>FLT3</i>-ITD (45 out of 165 initial diagnosis samples) and 16% of cases (26 mutations in 25 samples) with point mutations of <i>FLT</i>. Other commonly observed mutated genes include <i>WT1</i> (14%), <i>NRAS</i> (10%), <i>KRAS</i> (4%), <i>ETV6</i> (1%), and <i>EZH2</i> (1%). Interestingly, somatic mutations in known leukaemia-related genes (for example, <i>DNMT3A</i>, <i>NPM1</i>, <i>TET2</i>, <i>IDH1</i>, <i>IDH2</i>, and <i>ASXL1</i>) were absent or rarely observed in APML.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d28887e589>Thrombosis in acute promyelocytic leukaemia</h2><p class="" id=d28887e592>Whereas bleeding complications are common in APML, thrombotic events occurring before and during therapy are not uncommon. The incidence of thrombotic events appeared to be higher in patients who received ATRA compared with those in the pre-ATRA period<sup><a href="#ref-27">27</a></sup>. The largest study reported an incidence of 5% (39 out of 739) in patients who received ATRA-CT<sup><a href="#ref-28">28</a></sup>. The incidence increased to 9% in patients who received ATRA and tranexamic acid<sup><a href="#ref-17">17</a></sup>. Rashidi <i>et al.</i> conducted a careful review on the reported cases of thrombotic events in APML treated with an ATRA-containing regime<sup><a href="#ref-29">29</a></sup>. In the 94 cases collated from the literature review, it was observed that more than 80% of such events occurred before or during induction therapy and that deep vein thrombosis/pulmonary embolism, cardiac events, and cerebrovascular accidents constituted more than 75% of all cases. The incidence was fairly similar between those occurring before and during treatment with ATRA, possibly suggesting that ATRA therapy would not alter the thrombotic risk in APML. The underlying pathophysiology of thrombosis in this small subgroup of APML is still unclear. Treatment-related factors such as the use of ATRA, tranexamic acid, or even a chemotherapeutic agent might have increased the risk of thrombosis<sup><a href="#ref-18">18</a>,<a href="#ref-19">19</a>,<a href="#ref-30">30</a></sup>. Disease-related factors such as a higher WBC count, type of PML/RARa transcript, <i>FLT3</i>/ITD mutation, and positivity for CD2 or CD15 were reported to be associated with thrombosis in a large study of patients who received ATRA, CT, and prophylactic tranexamic acid<sup><a href="#ref-17">17</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d28887e635>Update on acute promyelocytic leukaemia treatment</h2><p class="" id=d28887e638>Since the introduction of ATRA into the treatment of APML slightly more than three decades ago, the clinical outcome of this deadly disease has changed completely<sup><a href="#ref-5">5</a></sup>. In the pre-ATRA era, anthracycline-based CT was the standard of treatment and reported CR rates were 75 to 80%<sup><a href="#ref-31">31</a>,<a href="#ref-32">32</a></sup>. However, the median duration of remission was only 11 to 25 months, and only 35 to 45% were cured by CT alone. Many subsequent clinical trials that incorporated ATRA into anthracycline-based CT have further improved the CR rates to 90 to 95% and DFS to around 70% or more (<a href="#T2">Table 2</a>).</p><div class="table-wrap panel clearfix"><a name=T2 class=n-a></a><div class=caption><h3>Table 2. Outcome in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid-based regimens.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d28887e666 class=n-a></a><thead><a name=d28887e668 class=n-a></a><tr><a name=d28887e670 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d28887e672 class=n-a></a>Reference group</th><th align=left colspan=1 rowspan=1 valign=top><a name=d28887e675 class=n-a></a>Number</th><th align=left colspan=1 rowspan=1 valign=top><a name=d28887e678 class=n-a></a>Complete<br class=br>remission, %</th><th align=left colspan=1 rowspan=1 valign=top><a name=d28887e683 class=n-a></a>Disease-free survival, %</th><th align=left colspan=1 rowspan=1 valign=top><a name=d28887e686 class=n-a></a>Overall survival, %</th></tr></thead><tbody><a name=d28887e691 class=n-a></a><tr><a name=d28887e693 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e695 class=n-a></a>Tallman <i>et al.</i><sup><a href="#ref-61">61</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e703 class=n-a></a>350</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e706 class=n-a></a>ATRA: 70<br class=br>CT: 73</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e711 class=n-a></a>ATRA: 69 (5 years)<br class=br>CT: 29 (5 years)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e716 class=n-a></a>ATRA: 69 (5 years)<br class=br>CT: 45 (5 years)</td></tr><tr><a name=d28887e722 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e724 class=n-a></a>Fenaux <i>et al.</i><sup><a href="#ref-68">68</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e732 class=n-a></a>ATRA: 54<br class=br>CT: 47</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e737 class=n-a></a>ATRA: 91<br class=br>CT: 81</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e742 class=n-a></a>EFS at 12 months<br class=br>ATRA: 79<br class=br>CT: 50</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e749 class=n-a></a></td></tr><tr><a name=d28887e752 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e754 class=n-a></a>Avvisati <i>et al.</i><sup><a href="#ref-69">69</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e762 class=n-a></a>807</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e765 class=n-a></a>94.3</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e768 class=n-a></a>EFS: 68.9 (12 years)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e771 class=n-a></a>76.5 (12 years)</td></tr><tr><a name=d28887e775 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e777 class=n-a></a>Iland <i>et al.</i><sup><a href="#ref-53">53</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e785 class=n-a></a>101</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e788 class=n-a></a>90</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e791 class=n-a></a>71 (4 years)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e794 class=n-a></a>84 (4 years)</td></tr><tr><a name=d28887e798 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e800 class=n-a></a>Sanz <i>et al.</i><sup><a href="#ref-70">70</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e808 class=n-a></a>560</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e811 class=n-a></a>91</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e814 class=n-a></a>84 (5 years)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e817 class=n-a></a>82 (5 years)</td></tr><tr><a name=d28887e822 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e824 class=n-a></a>Asou <i>et al.</i><sup><a href="#ref-71">71</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e832 class=n-a></a>283</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e835 class=n-a></a>94</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e838 class=n-a></a>68.5 (6 years)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e841 class=n-a></a>83.9 (6 years)</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d28887e849 class=n-a></a><p id=d28887e851> ATRA, all-trans retinoic acid; CT, chemotherapy; EFS, event-free survival.</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d28887e860>Moving from chemotherapy-based to chemotherapy-free treatment</h2><p class="" id=d28887e863>The use of ATO in the treatment of APML was first reported by a Chinese group from Harbin Medical University in 1996<sup><a href="#ref-33">33</a></sup>. Thirty newly diagnosed and 42 relapsed APML patients received single-agent ATO. CR rates of 73% and 52%, respectively, were observed. Another group, from the Shanghai Institute of Hematology, has reported high CR rates in newly diagnosed APML and relapsed cases (85.7% and 83.9%, respectively), further confirming the efficacy of ATO monotherapy<sup><a href="#ref-34">34</a></sup>. Interestingly, ATO monotherapy did not result in significant myelosuppression in these early cohorts. These early observations have led to a plethora of case series and clinical trials internationally, subsequently establishing ATO as the second line of treatment<sup><a href="#ref-35">35</a><a href="#ref-39">39</a></sup>. As a single agent, ATO is capable of inducing CR in 85 to 90% of relapsed cases. Besides having a high CR rate, ATO is capable of penetrating the bloodbrain barrier, making it an ideal salvage treatment because central nervous system diseases have been reported in approximately 10% of relapsed APML<sup><a href="#ref-40">40</a><a href="#ref-42">42</a></sup>. Upfront monotherapy with ATO has been performed since the early days of ATO use, and the results of long-term follow-up of these case series have been reported. A case series with elderly APML patients who were not fit for CT has shown a durable remission and results comparable to those of standard ATRA-CT in younger patients<sup><a href="#ref-43">43</a></sup>. The 10-year cumulative incidence of relapse was 10.3%, which compared favourably to ATRA-CT. In a separate study, single-agent ATO in patients with newly diagnosed APML provided a 5-year DFS of 80%, and minimal short-term toxicity and no long-term toxicity have been observed thus far<sup><a href="#ref-44">44</a>,<a href="#ref-45">45</a></sup>.</p><p class="" id=d28887e900>Early pre-clinical studies demonstrated synergistic activity when ATRA was combined with ATO in mouse studies<sup><a href="#ref-34">34</a>,<a href="#ref-35">35</a></sup>. With the long-term safety and efficacy data available for ATO, it is rational to combine ATO with ATRA in upfront treatment for APML. The group from the Shanghai Institute of Hematology was the first to report the use of this combination, in a cohort of 85 patients with newly diagnosed APML<sup><a href="#ref-46">46</a>,<a href="#ref-47">47</a></sup>. The group reported a high CR rate (94.1%) and a 5-year EFS and OS of 89.2% and 91.7%, respectively. The toxicities were mild and reversible. The group has also found that poor prognostic factors such as high WBC count (&gt;10  10<sup>9</sup>/L) did not influence the outcome. Subsequently, more groups have reported the use of ATRA/ATO in newly diagnosed patients (<a href="#T3">Table 3</a>)<sup><a href="#ref-38">38</a>,<a href="#ref-47">47</a><a href="#ref-52">52</a></sup>.</p><div class="table-wrap panel clearfix"><a name=T3 class=n-a></a><div class=caption><h3>Table 3. Summary of the studies using all-trans retinoic acid/arsenic trioxide as upfront treatment.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d28887e944 class=n-a></a><thead><a name=d28887e946 class=n-a></a><tr><a name=d28887e948 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d28887e950 class=n-a></a>References</th><th align=left colspan=1 rowspan=1 valign=top><a name=d28887e953 class=n-a></a>Year</th><th align=left colspan=1 rowspan=1 valign=top><a name=d28887e956 class=n-a></a>Number</th><th align=left colspan=1 rowspan=1 valign=top><a name=d28887e959 class=n-a></a>Complete<br class=br>remission rate</th><th align=left colspan=1 rowspan=1 valign=top><a name=d28887e964 class=n-a></a>Event-free<br class=br>survival</th><th align=left colspan=1 rowspan=1 valign=top><a name=d28887e970 class=n-a></a>Overall survival</th><th align=left colspan=1 rowspan=1 valign=top><a name=d28887e973 class=n-a></a>Remarks</th></tr></thead><tbody><a name=d28887e978 class=n-a></a><tr><a name=d28887e980 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e982 class=n-a></a>Estey <i>et al.</i><sup><a href="#ref-38">38</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e990 class=n-a></a>2006</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e993 class=n-a></a>Low risk: 25<br class=br>High risk: 19</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e998 class=n-a></a>Low risk: 96%<br class=br>High risk: 79%</td><td align=left colspan=1 rowspan=1><a name=d28887e1003 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d28887e1006 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1008 class=n-a></a>Non-randomised. Median follow-up of 16 months. No relapse in the low-risk group. Three relapsed in the high-risk group. Fifteen high-risk patients received an additional single dose of GO 9 mg/m<sup>2</sup> on day 1, and three had additional idarubicin chemotherapy.</td></tr><tr><a name=d28887e1015 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1017 class=n-a></a>Ravandi <i>et al.</i><sup><a href="#ref-48">48</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1025 class=n-a></a>2008</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1028 class=n-a></a>Low risk: 56<br class=br>High risk: 26</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1033 class=n-a></a>Low risk: 95%<br class=br>High risk: 81%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1038 class=n-a></a>3-year EFS<br class=br>Low risk: 89.2%<br class=br>High risk: 64.6%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1046 class=n-a></a>3-year OS<br class=br>Low risk: 89.2%<br class=br>High risk: 75.4%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1053 class=n-a></a>Non-randomised. Median follow-up of 99 weeks. Included all risk groups. High-risk patients received an additional dose of GO 9 mg/m<sup>2</sup> on day 1, and those who developed leukocytosis during treatment in the low-/intermediate-risk group received additional GO as well.</td></tr><tr><a name=d28887e1060 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1062 class=n-a></a>Hu <i>et al.</i><sup><a href="#ref-47">47</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1070 class=n-a></a>2009</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1073 class=n-a></a>85</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1076 class=n-a></a>94.10%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1079 class=n-a></a>5-year EFS: 89.2%<br class=br>5-year RFS: 94.8%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1085 class=n-a></a>5-year OS: 91.7%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1088 class=n-a></a>Non-randomised. Included all risk groups.</td></tr><tr><a name=d28887e1092 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1094 class=n-a></a>Lo-Coco <i>et al.</i><sup><a href="#ref-49">49</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1102 class=n-a></a>2013</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1105 class=n-a></a>ATRA-ATO: 77<br class=br>ATRA-CT: 79</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1110 class=n-a></a>ATRA-ATO: 100%<br class=br>ATRA-CT: 95%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1115 class=n-a></a>2-year EFS<br class=br>ATRA-ATO: 97%<br class=br>ATRA-CT: 86%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1123 class=n-a></a>2-year OS<br class=br>ATRA-ATO: 99%<br class=br>ATRA-CT: 91%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1130 class=n-a></a>Randomised. Included only low- and intermediate-risk patients. Median follow-up of 34.4 months.</td></tr><tr><a name=d28887e1134 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1136 class=n-a></a>Burnett <i>et al.</i><sup><a href="#ref-50">50</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1144 class=n-a></a>2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1147 class=n-a></a>ATRA-ATO: 116<br class=br>ATRA-CT: 119</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1152 class=n-a></a>ATRA-ATO: 94%<br class=br>ATRA-CT: 89%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1157 class=n-a></a>4-year EFS<br class=br>ATRA-ATO: 91%<br class=br>ATRA-CT: 70%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1165 class=n-a></a>4-year OS<br class=br>ATRA-ATO: 93%<br class=br>ATRA-CT: 89%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1172 class=n-a></a>Randomised. Included all risk groups. Low/intermediate risk, n = 178; high risk, n = 57. High-risk group received one dose of GO 6 mg/m<sup>2</sup> during induction.</td></tr><tr><a name=d28887e1180 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1182 class=n-a></a>Abaza <i>et al.</i><sup><a href="#ref-51">51</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1190 class=n-a></a>2016</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1193 class=n-a></a>Low risk: 133<br class=br>High risk: 54</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1198 class=n-a></a>Low risk: 95.5%<br class=br>High risk: 96.3%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1203 class=n-a></a>5-year EFS<br class=br>Low risk: 87%<br class=br>High risk: 81%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1211 class=n-a></a>5-year OS<br class=br>Low risk: 89%<br class=br>High risk: 86%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1218 class=n-a></a>Non-randomised. Included all risk groups. High-risk patients received an additional dose of GO 9 mg/m<sup>2</sup> on day 1, and those who developed leukocytosis during treatment in the low-/intermediate-risk group received additional GO as well.</td></tr><tr><a name=d28887e1225 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1227 class=n-a></a>Platzbecker <i>et al.</i><sup><a href="#ref-52">52</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1235 class=n-a></a>2016</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1238 class=n-a></a>ATRA-ATO: 127<br class=br>ATRA-CT: 136</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1243 class=n-a></a>ATRA-ATO: 100%<br class=br>ATRA-CT: 97%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1248 class=n-a></a>4-year EFS<br class=br>ATRA-ATO: 97.3%<br class=br>ATRA-CT: 80.0%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1256 class=n-a></a>4-year OS<br class=br>ATRA-ATO: 99.2%<br class=br>ATRA-CT: 92.6%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1263 class=n-a></a>Randomised. Included only the low-/intermediate-risk group.</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d28887e1271 class=n-a></a><p id=d28887e1273> ATRA-ATO, all-trans retinoic acid plus arsenic trioxide; ATRA-CT, all-trans retinoic acid plus chemotherapy; EFS, event-free survival; GO, gemtuzumab ozogamicin; OS, overall survival.</p></div></div></div><p class="" id=d28887e1279>The final report of the randomised Italian-German APL0406 trial was recently published, confirming the efficacy and safety of ATRA/ATO, especially in the low-risk group<sup><a href="#ref-52">52</a></sup>. This was an expanded cohort of the randomised controlled trial reported in 2013 by the GIMEMA-SAL-AMLSG study groups<sup><a href="#ref-49">49</a></sup>. In total, 263 patients with newly diagnosed non-high-risk APML were accrued and randomly assigned to ATRA-ATO or ATRA-CT in a 1:1 ratio. CR rates of 100% and 97% were reported in the ATRA-ATO and ATRA-CT arms, respectively (<i>p</i> = 0.12). Significant superior EFS, cumulative incidence of relapse, and OS at 50 months were observed in the ATRA-ATO arm (97.3% versus 80%, <i>p</i> = 0.001; 1.9% versus 13.9%, <i>p</i> = 0.0013; and 99.2% versus 92.6%, <i>p</i> = 0.0073, respectively). Of note, induction death occurred only in the ATRA-CT arm (four patients, or 3%).</p><p class="" id=d28887e1304>The MD Anderson group has also updated their expanded cohort of 187 patients with a median follow-up of 47.6 months<sup><a href="#ref-51">51</a></sup>. It was a non-randomised trial using ATO-ATRA upfront in all risk groups. However, the high-risk group was allocated to receive an additional gemtuzumab ozogamicin (GO) dose on day 1 of induction. Those who developed leukocytosis in low or intermediate risk during ATRA-ATO therapy were also given a dose of GO to control rising WBC count. Forty-five patients in the high-risk group received GO, and seven others received idarubicin (when GO was not available). In the low-risk group, 60 patients received cytoreduction therapy for leukocytosis. Fifty-one patients received GO and the remaining nine received idarubicin for cytoreduction. In total, 59.9% of the patients received cytoreductive therapy. The study recorded high CR rates in both low- and high-risk groups and no significant difference in EFS and OS between the risk groups.</p><p class="" id=d28887e1311>MRC UK has also recently reported a large cohort of patients with newly diagnosed APML receiving ATRA-ATO as upfront treatment<sup><a href="#ref-43">43</a>,<a href="#ref-50">50</a></sup>. It was a randomised study and formed part of the AML17 study. In total, 235 patients were enrolled from 81 centres in the UK. The comparative arm received ATRA plus idarubicin as induction followed by ATRA-CT consolidation. It is important to note that the ATO dose and schedule were rather different from those reported in other studies. A higher ATO dose was given during the first week of induction but for only 5 days. In subsequent weeks, a higher dosage (0.25 mg/m<sup>2</sup>) was given again twice weekly. However, the total ATO dose for the whole induction and the consolidation cycles was significantly higher in the AML17 trial compared with other groups (<a href="#T4">Table 4</a>). Twenty-eight (93%) of 30 high-risk patients in the ATRA-ATO arm received GO (the remaining two high-risk patients did not because there was no GO available on-site, and anthracycline was given instead). Furthermore, seven low-risk patients were also given GO for their rising WBC count. The strategy of using GO in the high-risk group and rising WBC count in the low-risk group was similar to that reported by the MD Anderson group. A high CR rate of 94% was documented in the ATRA-ATO arm compared with 89% in the ATRA-CT arm but was not statistically significant. The 4-year EFS was significantly better in the ATRA-ATO arm than in the ATRA-CT arm (91% versus 70%, <i>p</i> = 0.002). This significant benefit was apparent in low-risk patients4-year EFS of 92% (95% confidence interval [CI] 8497%) in the ATRA-ATO arm versus<i></i> 71% in the ATRA-CT arm; hazard ratio (HR) 0.34 (0.150.75), <i>p</i> = 0.008but not in the high-risk groups. The 4-year EFS and OS of this cohort appeared to be comparable to those of other groups (92% and 95%, respectively). This opens up the possibility of an alternative dosing schedule for the ATRA-ATO regimen, which is more pragmatic.</p><div class="table-wrap panel clearfix"><a name=T4 class=n-a></a><div class=caption><h3>Table 4. Comparing the arsenic trioxide dosing between AML17 and APL0406 trials.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d28887e1347 class=n-a></a><thead><a name=d28887e1349 class=n-a></a><tr><a name=d28887e1351 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d28887e1353 class=n-a></a></th><th align=left colspan=1 rowspan=1><a name=d28887e1355 class=n-a></a>AML17 trial</th><th align=left colspan=1 rowspan=1><a name=d28887e1358 class=n-a></a>APL0406 trial</th></tr></thead><tbody><a name=d28887e1363 class=n-a></a><tr><a name=d28887e1365 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1367 class=n-a></a>Induction cycle</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1370 class=n-a></a>Week 1: 0.3 mg/kg (day 15)<br class=br>Week 28: 0.25 mg/kg twice weekly</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1375 class=n-a></a>0.15 mg/kg per day (up to 60 days)</td></tr><tr><a name=d28887e1379 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1381 class=n-a></a>Consolidation (four cycles)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1384 class=n-a></a>Week 1: 0.3 mg/kg (day 15)<br class=br>Week 24: 0.25 mg/kg twice weekly</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1389 class=n-a></a>0.15 mg/kg 5 days weekly for 4 weeks</td></tr><tr><a name=d28887e1393 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1395 class=n-a></a>Total arsenic trioxide dose</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1398 class=n-a></a>25 mg/kg</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28887e1401 class=n-a></a>21 mg/kg</td></tr></tbody></table></div><p class="" id=d28887e1408>The superiority of ATRA-ATO over the conventional ATRA-CT regimen is undisputable in the low- and intermediate-risk group but not in the high-risk group. The addition of GO to the ATRA-ATO regimen in the high-risk group in most recently published studies has muddled the true efficacy of ATRA-ATO in this risk group. Although the cohort from Hu <i>et al.</i> did shed some light on the potential efficacy of ATRA-ATO in the high-risk group, the result came from a small and non-randomly assigned cohort<sup><a href="#ref-47">47</a></sup>. GO is currently still not available outside the clinical trial setting, hence using ATRA-ATO alone for the high-risk group is not recommended. More data on the use of ATRA-ATO in the high-risk group are needed to support this recommendation. Nevertheless, in the APL4 trial by the AustraliaNew Zealand group, idarubicin was incorporated into the ATRA-ATO regimen during induction followed by ATRA-ATO consolidation therapy in all risk groups. Among the 124 patients, four induction deaths were reported and two patients withdrew consent. The remaining 118 patients achieved haematologic CR<sup><a href="#ref-53">53</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d28887e1425>Paediatric acute promyelocytic leukaemia</h2><p class="" id=d28887e1428>The incidence of APML in children is much lower compared with adults. It constitutes only 5 to 7% of AML in children<sup><a href="#ref-20">20</a><a href="#ref-22">22</a></sup>. The optimal therapy is still not established, but the increasing use of ATRA-CT and the ATRA-ATO regimen has largely improved the outcome<sup><a href="#ref-54">54</a></sup>. Adult protocols were often applied to paediatric APML. The outcomes appeared to be comparable to those of the adult population<sup><a href="#ref-22">22</a></sup>. Nevertheless, there is concern over the long-term side effects, particularly with ATO. In a small series reported by a German group, 11 children with low-risk APML received ATRA-ATO and all developed hyperleukocytosis. Two patients experienced reversible severe side effects. One developed osteonecroses at both femurs, seizures, and posterior reversible encephalopathy syndrome, and the other patient had an abducens paresis<sup><a href="#ref-55">55</a></sup>. In contrast, two Chinese groups reported an excellent long-term outcome with minimal chronic toxicities in patients who received ATO<sup><a href="#ref-24">24</a>,<a href="#ref-56">56</a>,<a href="#ref-57">57</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d28887e1463>Incidence of differentiation syndrome and the effectiveness of prophylaxis</h2><p class="" id=d28887e1466>DS is a life-threatening condition associated more commonly with ATRA- and ATO-based treatment, although DS could occur without ATRA/ATO. It is characterised by fever, peripheral oedema, pulmonary infiltrates, hypoxemia, respiratory distress, hypotension, renal and hepatic dysfunction, and serositis resulting in pleural and pericardial effusions. Rates of incidence of DS in the ATRA-CT era were reported to be around 25% in the large series PETHEMA LPA96 and LPA99 trials<sup><a href="#ref-28">28</a></sup> and 30% in ATO monotherapy in the newly diagnosed or relapsed setting<sup><a href="#ref-58">58</a>,<a href="#ref-59">59</a></sup>; a more recent ATRA-ATO regimen reported incidences of between 15 and 20% with steroid prophylaxis<sup><a href="#ref-48">48</a>,<a href="#ref-49">49</a></sup>. The use of steroid was based on observations in the LPA96 and LPA99 trials, where patients in LPA99 were given prednisolone prophylaxis from the start whereas LPA96 used selective intravenous dexamethasone prophylaxis in patients with a WBC count of more than 5  10<sup>9</sup>/L. The incidence of severe DS was significantly higher in the latter. In a combined analysis of the two trials, presenting WBC count of more than 5  10<sup>9</sup>/L was an independent predictor of severe DS<sup><a href="#ref-28">28</a></sup> In a separate study, those with DS were found to have higher WBC count peaks compared with those without DS. However, some patients who developed leukocytosis during the treatment never progressed to DS<sup><a href="#ref-60">60</a></sup>. More recently, the large UK MRC AML17 trial reported an incidence of 21% in the ATRA-ATO arm without the use of steroid prophylaxis, although those who developed leukocytosis were given an additional dose of GO<sup><a href="#ref-50">50</a></sup>. The rate was close to those reported in the studies with steroid prophylaxis. This raised the question of the effectiveness of prophylactic steroids to prevent DS. Although there has been no direct evidence to support the routine use of steroid prophylaxis, its use in patients with high presenting WBC count is appropriate. Timely administration of cytoreductive therapy such as cytarabine in patients with rising WBC count during treatment with an ATRA/ATO-containing regimen would reduce the risk of DS development, even though this was also based on indirect evidence.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d28887e1510>Do we still need maintenance therapy in the era of all-trans retinoic acid/arsenic trioxide?</h2><p class="" id=d28887e1513>Maintenance therapy was originally part of the design of the ATRA-CT regimen, and a subsequent randomisation trial confirmed the benefit of such therapy<sup><a href="#ref-61">61</a>,<a href="#ref-62">62</a></sup>. However, in the era of ATRA-ATO, the role of maintenance has come into question. The Intergroup APL0406 randomised phase III trial, which did not include maintenance therapy for those who received ATRA plus ATO, has demonstrated the non-inferiority of ATRA plus ATO compared with ATRA plus idarubicin (AIDA) in low- or intermediate-risk APL<sup><a href="#ref-52">52</a></sup>. In the UK MRC trial, the absence of maintenance therapy in the ATRA-ATO group similarly confirmed the non-inferiority of ATRA plus ATO compared with AIDA in all risk groups<sup><a href="#ref-50">50</a></sup>. In a non-inferiority study, 105 adults with newly diagnosed low- or intermediate-risk APL underwent induction with ATRA-CT followed by consolidation that included ATO<sup><a href="#ref-63">63</a></sup>. The 68 patients who achieved complete molecular response were randomly assigned to observation alone or maintenance therapy with ATRA, 6-mercaptopurine (6-MP), and methotrexate. After a median follow-up of 36 months, no patients who achieved complete molecular response have relapsed.</p><p class="" id=d28887e1535>In a recent study reported by the Japan Adult Leukaemia Study Group, tamibarotene, a synthetic retinoic acid, might improve the RFS in high-risk APML<sup><a href="#ref-64">64</a></sup>. In this phase III study, 269 patients who achieved CR after ATRA-CT induction and consolidation cycles were randomly assigned to either ATRA or tamibarotene maintenance. The RFS rates at 4 years were 84% for the ATRA arm and 91% for the tamibarotene arm (HR 0.54, 95% CI 0.26 to 1.13). However, when the analysis was confined to 52 high-risk patients, the difference was statistically significant with 4-year RFS rates of 58% for the ATRA arm and 87% for the tamibarotene arm (HR 0.26, 95% CI 0.07 to 0.95).</p><p class="" id=d28887e1542>In the low-/intermediate-risk group where ATRA-ATO has now become the standard of treatment, conventional maintenance therapy can be safely omitted. In the high-risk group, the omission of maintenance can be considered if an ATRAATO-containing regimen is used in conjunction with another cytotoxic agent such as idarubicin and has achieved molecular remission at the end of consolidation.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d28887e1548>Moving towards total oral therapy in the near future</h2><p class="" id=d28887e1551>Zhu <i>et al.</i> has recently reported the use of oral arsenic in combination with ATRA and showed a non-inferiority outcome when compared with intravenous ATO plus ATRA<sup><a href="#ref-65">65</a></sup>. In total, 242 patients with APML were randomly assigned in a 1:1 fashion to oral tetra-arsenic tetra-sulphide (As4S4) (60 mg/kg) or ATO (0.16 mg/kg) combined with ATRA during induction therapy. After achieving CR, all patients received three further courses of consolidation CT followed by maintenance therapy with sequential ATRA followed by As4S4 or ATO for 2 years. With a median follow-up time of 39 months, DFS rates at 2 years were 98.1% (106 out of 108) in the As4S4 group and 95.5% (107 out of 112) in the ATO group. The CR rate was not significantly different between the two groups (As4S4 versus ATO, 99.1% versus 97.2%, respectively; <i>p</i> = 0.62). The OS rates at 3 years were 99.1% for As4S4 and 96.6% for ATO (<i>p</i> = 0.18). The rates of adverse events were similar. In a later study conducted by the same group, Zhu <i>et al.</i> demonstrated the feasibility of out-of-hospital treatment using oral As4S4 and ATRA without CT<sup><a href="#ref-66">66</a></sup>. In total, 20 consecutive non-high-risk APML patients were enrolled in this pilot study. Complete molecular remission was achieved in all patients. Post-remission therapy included oral As4S4 on a schedule of 4 weeks on/4 weeks off and ATRA on a schedule of 2 weeks on/2 weeks off for 7 months. At the median follow-up of 14 months (range of 8 to 19 months), no patient had molecular relapse. DS occurred in two patients and grade 3 or 4 adverse liver toxicities were observed in three patients. A prospective multicentre, randomised trial comparing oral As4S4 and ATRA with ATO and ATRA is ongoing in China.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d28887e1578>Conclusions</h2><p class="" id=d28887e1581>Similar to the success story of CML, the amazing journey of treatment transformation in APML has been a rare success story in cancer treatment. Both have paved the way in which cancer should be treatedmolecularly targeted, total oral administration, highly effective, and yet with minimal toxicity.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d28887e1 class=n-a></a><h2 class=main-title id=d29137>Competing interests</h2><p class=metadata-entry><a name=d28887e85 class=n-a></a><p id=d28887e87> The authors declare that they have no competing interests.</p></p></div><div class=back-section><a name=d28887e1 class=n-a></a><h2 class=main-title id=d29139>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d28887e1588 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d29348>References</h2><div class="section ref-list"><a name=d28887e1588 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d28887e1595 class=n-a></a>de Th H, Chomienne C, Lanotte M, <i> et al.</i>: The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. <i>Nature.</i> 1990; <b>347</b>(6293): 55861. <a target=xrefwindow id=d28887e1606 href="http://www.ncbi.nlm.nih.gov/pubmed/2170850">PubMed Abstract </a> | <a target=xrefwindow id=d28887e1609 href="http://dx.doi.org/10.1038/347558a0">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d28887e1618 class=n-a></a>Melnick A, Licht JD: Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. <i>Blood.</i> 1999; <b>93</b>(10): 3167215. <a target=xrefwindow id=d28887e1626 href="http://www.ncbi.nlm.nih.gov/pubmed/10233871">PubMed Abstract </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d28887e1635 class=n-a></a>Liu TX, Zhang JW, Tao J, <i> et al.</i>: Gene expression networks underlying retinoic acid-induced differentiation of acute promyelocytic leukemia cells. <i>Blood.</i> 2000; <b>96</b>(4): 1496504. <a target=xrefwindow id=d28887e1646 href="http://www.ncbi.nlm.nih.gov/pubmed/10942397">PubMed Abstract </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d28887e1655 class=n-a></a>Huang ME, Ye YC, Chen SR, <i> et al.</i>: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. <i>Blood.</i> 1988; <b>72</b>(2): 56772. <a target=xrefwindow id=d28887e1666 href="http://www.ncbi.nlm.nih.gov/pubmed/3165295">PubMed Abstract </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d28887e1675 class=n-a></a>Wang ZY, Chen Z: Acute promyelocytic leukemia: from highly fatal to highly curable. <i>Blood.</i> 2008; <b>111</b>(5): 250515. <a target=xrefwindow id=d28887e1683 href="http://www.ncbi.nlm.nih.gov/pubmed/18299451">PubMed Abstract </a> | <a target=xrefwindow id=d28887e1686 href="http://dx.doi.org/10.1182/blood-2007-07-102798">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d28887e1696 class=n-a></a>Chen Z, Brand NJ, Chen A, <i> et al.</i>: Fusion between a novel Krppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. <i>EMBO J.</i> 1993; <b>12</b>(3): 11617. <a target=xrefwindow id=d28887e1707 href="http://www.ncbi.nlm.nih.gov/pubmed/8384553">PubMed Abstract </a> | <a target=xrefwindow id=d28887e1710 href="http://www.ncbi.nlm.nih.gov/pmc/articles/413318">Free Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d28887e1719 class=n-a></a>Redner RL, Rush EA, Faas S, <i> et al.</i>: The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. <i>Blood.</i> 1996; <b>87</b>(3): 8826. <a target=xrefwindow id=d28887e1730 href="http://www.ncbi.nlm.nih.gov/pubmed/8562957">PubMed Abstract </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d28887e1739 class=n-a></a>Wells RA, Hummel JL, De Koven A, <i> et al.</i>: A new variant translocation in acute promyelocytic leukaemia: molecular characterization and clinical correlation. <i>Leukemia.</i> 1996; <b>10</b>(4): 73540. <a target=xrefwindow id=d28887e1750 href="http://www.ncbi.nlm.nih.gov/pubmed/8618456">PubMed Abstract </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d28887e1759 class=n-a></a>Arnould C, Philippe C, Bourdon V, <i> et al.</i>: The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia. <i>Hum Mol Genet.</i> 1999; <b>8</b>(9): 17419. <a target=xrefwindow id=d28887e1770 href="http://www.ncbi.nlm.nih.gov/pubmed/10441338">PubMed Abstract </a> | <a target=xrefwindow id=d28887e1773 href="http://dx.doi.org/10.1093/hmg/8.9.1741">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d28887e1782 class=n-a></a>Yamamoto Y, Tsuzuki S, Tsuzuki M, <i> et al.</i>: BCOR as a novel fusion partner of retinoic acid receptor alpha in a t(X;17)(p11;q12) variant of acute promyelocytic leukemia. <i>Blood.</i> 2010; <b>116</b>(20): 427483. <a target=xrefwindow id=d28887e1793 href="http://www.ncbi.nlm.nih.gov/pubmed/20807888">PubMed Abstract </a> | <a target=xrefwindow id=d28887e1796 href="http://dx.doi.org/10.1182/blood-2010-01-264432">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727821467"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28887e1805 class=n-a></a>Ichikawa S, Ichikawa S, Ishikawa I, <i> et al.</i>: Successful treatment of acute promyelocytic leukemia with a t(X;17)(p11.4;q21) and <i>BCOR-RARA</i> fusion gene. <i>Cancer Genet.</i> 2015; <b>208</b>(4): 1623. <a target=xrefwindow id=d28887e1819 href="http://www.ncbi.nlm.nih.gov/pubmed/25790901">PubMed Abstract </a> | <a target=xrefwindow id=d28887e1823 href="http://dx.doi.org/10.1016/j.cancergen.2015.01.008">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727821467">F1000 Recommendation</a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727821468"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28887e1837 class=n-a></a>Lucena-Araujo AR, Kim HT, Jacomo RH, <i> et al.</i>: Internal tandem duplication of the <i>FLT<sub>3</sub></i> gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-<i>trans</i> retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study. <i>Ann Hematol.</i> 2014; <b>93</b>(12): 200110. <a target=xrefwindow id=d28887e1857 href="http://www.ncbi.nlm.nih.gov/pubmed/24981688">PubMed Abstract </a> | <a target=xrefwindow id=d28887e1860 href="http://dx.doi.org/10.1007/s00277-014-2142-9">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727821468">F1000 Recommendation</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718155972"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28887e1873 class=n-a></a>Poire X, Moser BK, Gallagher RE, <i> et al.</i>: Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of <i>FLT3</i> mutations and complex karyotype. <i>Leuk Lymphoma.</i> 2014; <b>55</b>(7): 152332. <a target=xrefwindow id=d28887e1887 href="http://www.ncbi.nlm.nih.gov/pubmed/24160850">PubMed Abstract </a> | <a target=xrefwindow id=d28887e1891 href="http://dx.doi.org/10.3109/10428194.2013.842985">Publisher Full Text </a> | <a target=xrefwindow id=d28887e1894 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4273565">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718155972">F1000 Recommendation</a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726326089"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28887e1907 class=n-a></a>Cicconi L, Divona M, Ciardi C, <i> et al.</i>: PML-RAR kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy. <i>Leukemia.</i> 2016; <b>30</b>(10): 19871992. <a target=xrefwindow id=d28887e1918 href="http://www.ncbi.nlm.nih.gov/pubmed/27133819">PubMed Abstract </a> | <a target=xrefwindow id=d28887e1921 href="http://dx.doi.org/10.1038/leu.2016.122">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726326089">F1000 Recommendation</a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d28887e1934 class=n-a></a>Beitinjaneh A, Jang S, Roukoz H, <i> et al.</i>: Prognostic significance of FLT<sub>3</sub> internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: a systematic review. <i>Leuk Res.</i> 2010; <b>34</b>(7): 8316. <a target=xrefwindow id=d28887e1948 href="http://www.ncbi.nlm.nih.gov/pubmed/20096459">PubMed Abstract </a> | <a target=xrefwindow id=d28887e1952 href="http://dx.doi.org/10.1016/j.leukres.2010.01.001">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726180028"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28887e1961 class=n-a></a>Testa U, Lo-Coco F: Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients. <i>Ann Hematol.</i> 2016; <b>95</b>(5): 67380. <a target=xrefwindow id=d28887e1969 href="http://www.ncbi.nlm.nih.gov/pubmed/26920716">PubMed Abstract </a> | <a target=xrefwindow id=d28887e1972 href="http://dx.doi.org/10.1007/s00277-016-2622-1">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726180028">F1000 Recommendation</a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d28887e1985 class=n-a></a>Breccia M, Avvisati G, Latagliata R, <i> et al.</i>: Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features. <i>Leukemia.</i> 2007; <b>21</b>(1): 7983. <a target=xrefwindow id=d28887e1996 href="http://www.ncbi.nlm.nih.gov/pubmed/16932337">PubMed Abstract </a> | <a target=xrefwindow id=d28887e1999 href="http://dx.doi.org/10.1038/sj.leu.2404377">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d28887e2009 class=n-a></a>Boles JC, Williams JC, Hollingsworth RM, <i> et al.</i>: Anthracycline treatment of the human monocytic leukemia cell line THP-1 increases phosphatidylserine exposure and tissue factor activity. <i>Thromb Res.</i> 2012; <b>129</b>(2): 197203. <a target=xrefwindow id=d28887e2020 href="http://www.ncbi.nlm.nih.gov/pubmed/21762960">PubMed Abstract </a> | <a target=xrefwindow id=d28887e2023 href="http://dx.doi.org/10.1016/j.thromres.2011.06.022">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d28887e2032 class=n-a></a>Marchetti M, Falanga A, Giovanelli S, <i> et al.</i>: All-<i>trans</i>-retinoic acid increases adhesion to endothelium of the human promyelocytic leukaemia cell line NB4. <i>Br J Haematol.</i> 1996; <b>93</b>(2): 3606. <a target=xrefwindow id=d28887e2046 href="http://www.ncbi.nlm.nih.gov/pubmed/8639429">PubMed Abstract </a> | <a target=xrefwindow id=d28887e2050 href="http://dx.doi.org/10.1046/j.1365-2141.1996.4911029.x">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d28887e2059 class=n-a></a>Testi AM, Biondi A, Lo Coco F, <i> et al.</i>: GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. <i>Blood.</i> 2005; <b>106</b>(2): 44753. <a target=xrefwindow id=d28887e2070 href="http://www.ncbi.nlm.nih.gov/pubmed/15677559">PubMed Abstract </a> | <a target=xrefwindow id=d28887e2073 href="http://dx.doi.org/10.1182/blood-2004-05-1971">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d28887e2082 class=n-a></a>Ortega JJ, Madero L, Martn G, <i> et al.</i>: Treatment with all-<i>trans</i> retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group. <i>J Clin Oncol.</i> 2005; <b>23</b>(30): 763240. <a target=xrefwindow id=d28887e2096 href="http://www.ncbi.nlm.nih.gov/pubmed/16234524">PubMed Abstract </a> | <a target=xrefwindow id=d28887e2100 href="http://dx.doi.org/10.1200/JCO.2005.01.3359">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d28887e2109 class=n-a></a>de Botton S, Coiteux V, Chevret S, <i> et al.</i>: Outcome of childhood acute promyelocytic leukemia with all-<i>trans</i>-retinoic acid and chemotherapy. <i>J Clin Oncol.</i> 2004; <b>22</b>(8): 140412. <a target=xrefwindow id=d28887e2123 href="http://www.ncbi.nlm.nih.gov/pubmed/15084614">PubMed Abstract </a> | <a target=xrefwindow id=d28887e2127 href="http://dx.doi.org/10.1200/JCO.2004.09.008">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727821470"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28887e2136 class=n-a></a>Breccia M, De Propris MS, Stefanizzi C, <i> et al.</i>: Negative prognostic value of CD34 antigen also if expressed on a small population of acute promyelocytic leukemia cells. <i>Ann Hematol.</i> 2014; <b>93</b>(11): 181923. <a target=xrefwindow id=d28887e2147 href="http://www.ncbi.nlm.nih.gov/pubmed/24912771">PubMed Abstract </a> | <a target=xrefwindow id=d28887e2150 href="http://dx.doi.org/10.1007/s00277-014-2130-0">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727821470">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d28887e2164 class=n-a></a>Zhou J, Zhang Y, Li J, <i> et al.</i>: Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia. <i>Blood.</i> 2010; <b>115</b>(9): 1697702. <a target=xrefwindow id=d28887e2175 href="http://www.ncbi.nlm.nih.gov/pubmed/20029047">PubMed Abstract </a> | <a target=xrefwindow id=d28887e2178 href="http://dx.doi.org/10.1182/blood-2009-07-230805">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/3050961"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28887e2187 class=n-a></a>Grimwade D, Hills RK, Moorman AV, <i> et al.</i>: Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. <i>Blood.</i> 2010; <b>116</b>(3): 35465. <a target=xrefwindow id=d28887e2198 href="http://www.ncbi.nlm.nih.gov/pubmed/20385793">PubMed Abstract </a> | <a target=xrefwindow id=d28887e2201 href="http://dx.doi.org/10.1182/blood-2009-11-254441">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/3050961">F1000 Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d28887e2214 class=n-a></a>Madan V, Shyamsunder P, Han L, <i> et al.</i>: Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. <i>Leukemia.</i> 2016; <b>30</b>(12): 2430. <a target=xrefwindow id=d28887e2225 href="http://www.ncbi.nlm.nih.gov/pubmed/27713533">PubMed Abstract </a> | <a target=xrefwindow id=d28887e2228 href="http://dx.doi.org/10.1038/leu.2016.237">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d28887e2237 class=n-a></a>Escudier SM, Kantarjian HM, Estey EH: Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid. <i>Leuk Lymphoma.</i> 1996; <b>20</b>(56): 4359. <a target=xrefwindow id=d28887e2245 href="http://www.ncbi.nlm.nih.gov/pubmed/8833399">PubMed Abstract </a> | <a target=xrefwindow id=d28887e2248 href="http://dx.doi.org/10.3109/10428199609052425">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/720031424"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28887e2257 class=n-a></a>Montesinos P, Bergua JM, Vellenga E, <i> et al.</i>: Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-<i>trans</i> retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. <i>Blood.</i> 2009; <b>113</b>(4): 77583. <a target=xrefwindow id=d28887e2271 href="http://www.ncbi.nlm.nih.gov/pubmed/18945964">PubMed Abstract </a> | <a target=xrefwindow id=d28887e2275 href="http://dx.doi.org/10.1182/blood-2008-07-168617">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/720031424">F1000 Recommendation</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d28887e2288 class=n-a></a>Rashidi A, Silverberg ML, Conkling PR, <i> et al.</i>: Thrombosis in acute promyelocytic leukemia. <i>Thromb Res.</i> 2013; <b>131</b>(4): 2819. <a target=xrefwindow id=d28887e2299 href="http://www.ncbi.nlm.nih.gov/pubmed/23266518">PubMed Abstract </a> | <a target=xrefwindow id=d28887e2302 href="http://dx.doi.org/10.1016/j.thromres.2012.11.024">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d28887e2312 class=n-a></a>Barbui T, Finazzi G, Falanga A: The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. <i>Blood.</i> 1998; <b>91</b>(9): 3093102. <a target=xrefwindow id=d28887e2320 href="http://www.ncbi.nlm.nih.gov/pubmed/9558362">PubMed Abstract </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d28887e2329 class=n-a></a>Cunningham I, Gee TS, Reich LM, <i> et al.</i>: Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. <i>Blood.</i> 1989; <b>73</b>(5): 111622. <a target=xrefwindow id=d28887e2340 href="http://www.ncbi.nlm.nih.gov/pubmed/2930837">PubMed Abstract </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d28887e2349 class=n-a></a>Sanz MA, Jarque I, Martn G, <i> et al.</i>: Acute promyelocytic leukemia. <i>Therapy results and prognostic factors</i>. <i>Cancer.</i> 1988; <b>61</b>(1): 713. <a target=xrefwindow id=d28887e2363 href="http://www.ncbi.nlm.nih.gov/pubmed/3422032">PubMed Abstract </a> | <a target="xrefwindow" id="d28887e2367" href="http://dx.doi.org/10.1002/1097-0142(19880101)61:1<7::AID-CNCR2820610103&gt;3.0.CO;2-6">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d28887e2376 class=n-a></a>Zhang P, W S, Hu LH: Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. <i>Chin J Hematol.</i> 1996; (17): 5.</span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d28887e2388 class=n-a></a>Niu C, Yan H, Yu T, <i> et al.</i>: Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. <i>Blood.</i> 1999; <b>94</b>(10): 331524. <a target=xrefwindow id=d28887e2399 href="http://www.ncbi.nlm.nih.gov/pubmed/10552940">PubMed Abstract </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d28887e2408 class=n-a></a>Soignet SL, Frankel SR, Douer D, <i> et al.</i>: United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. <i>J Clin Oncol.</i> 2001; <b>19</b>(18): 385260. <a target=xrefwindow id=d28887e2419 href="http://www.ncbi.nlm.nih.gov/pubmed/11559723">PubMed Abstract </a> | <a target=xrefwindow id=d28887e2422 href="http://dx.doi.org/10.1200/JCO.2001.19.18.3852">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d28887e2432 class=n-a></a>Shigeno K, Naito K, Sahara N, <i> et al.</i>: Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies. <i>Int J Hematol.</i> 2005; <b>82</b>(3): 2249. <a target=xrefwindow id=d28887e2443 href="http://www.ncbi.nlm.nih.gov/pubmed/16207595">PubMed Abstract </a> | <a target=xrefwindow id=d28887e2446 href="http://dx.doi.org/10.1532/IJH97.05044">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d28887e2455 class=n-a></a>Leoni F, Gianfaldoni G, Annunziata M, <i> et al.</i>: Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation. <i>Haematologica.</i> 2002; <b>87</b>(5): 4859. <a target=xrefwindow id=d28887e2466 href="http://www.ncbi.nlm.nih.gov/pubmed/12010661">PubMed Abstract </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d28887e2475 class=n-a></a>Estey E, Garcia-Manero G, Ferrajoli A, <i> et al.</i>: Use of all-<i>trans</i> retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. <i>Blood.</i> 2006; <b>107</b>(9): 346973. <a target=xrefwindow id=d28887e2489 href="http://www.ncbi.nlm.nih.gov/pubmed/16373661">PubMed Abstract </a> | <a target=xrefwindow id=d28887e2493 href="http://dx.doi.org/10.1182/blood-2005-10-4006">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d28887e2502 class=n-a></a>Yanada M, Tsuzuki M, Fujita H, <i> et al.</i>: Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. <i>Blood.</i> 2013; <b>121</b>(16): 3095102. <a target=xrefwindow id=d28887e2513 href="http://www.ncbi.nlm.nih.gov/pubmed/23412094">PubMed Abstract </a> | <a target=xrefwindow id=d28887e2516 href="http://dx.doi.org/10.1182/blood-2012-11-466862">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d28887e2525 class=n-a></a>Au WY, Tam S, Fong BM, <i> et al.</i>: Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy. <i>Blood.</i> 2008; <b>112</b>(9): 358790. <a target=xrefwindow id=d28887e2536 href="http://www.ncbi.nlm.nih.gov/pubmed/18703707">PubMed Abstract </a> | <a target=xrefwindow id=d28887e2539 href="http://dx.doi.org/10.1182/blood-2008-06-161000">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d28887e2548 class=n-a></a>Knipp S, Gattermann N, Schapira M, <i> et al.</i>: Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement. <i>Leuk Res.</i> 2007; <b>31</b>(11): 15857. <a target=xrefwindow id=d28887e2559 href="http://www.ncbi.nlm.nih.gov/pubmed/17416415">PubMed Abstract </a> | <a target=xrefwindow id=d28887e2562 href="http://dx.doi.org/10.1016/j.leukres.2007.03.007">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d28887e2572 class=n-a></a>Evans GD, Grimwade DJ: Extramedullary disease in acute promyelocytic leukemia. <i>Leuk Lymphoma.</i> 1999; <b>33</b>(34): 21929. <a target=xrefwindow id=d28887e2580 href="http://www.ncbi.nlm.nih.gov/pubmed/10221502">PubMed Abstract </a> | <a target=xrefwindow id=d28887e2583 href="http://dx.doi.org/10.3109/10428199909058422">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d28887e2592 class=n-a></a>Zhang Y, Zhang Z, Li J, <i> et al.</i>: Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia. <i>Cancer.</i> 2013; <b>119</b>(1): 11525. <a target=xrefwindow id=d28887e2603 href="http://www.ncbi.nlm.nih.gov/pubmed/22930197">PubMed Abstract </a> | <a target=xrefwindow id=d28887e2606 href="http://dx.doi.org/10.1002/cncr.27650">Publisher Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d28887e2615 class=n-a></a>Mathews V, George B, Chendamarai E, <i> et al.</i>: Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. <i>J Clin Oncol.</i> 2010; <b>28</b>(24): 386671. <a target=xrefwindow id=d28887e2626 href="http://www.ncbi.nlm.nih.gov/pubmed/20644086">PubMed Abstract </a> | <a target=xrefwindow id=d28887e2629 href="http://dx.doi.org/10.1200/JCO.2010.28.5031">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d28887e2638 class=n-a></a>Mathews V, George B, Lakshmi KM, <i> et al.</i>: Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. <i>Blood.</i> 2006; <b>107</b>(7): 262732. <a target=xrefwindow id=d28887e2649 href="http://www.ncbi.nlm.nih.gov/pubmed/16352810">PubMed Abstract </a> | <a target=xrefwindow id=d28887e2652 href="http://dx.doi.org/10.1182/blood-2005-08-3532">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d28887e2661 class=n-a></a>Shen ZX, Shi ZZ, Fang J, <i> et al.</i>: <i>All-trans</i> retinoic acid/As<sub>2</sub>O<sub>3</sub> combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. <i>Proc Natl Acad Sci U S A.</i> 2004; <b>101</b>(15): 532835. <a target=xrefwindow id=d28887e2682 href="http://www.ncbi.nlm.nih.gov/pubmed/15044693">PubMed Abstract </a> | <a target=xrefwindow id=d28887e2685 href="http://dx.doi.org/10.1073/pnas.0400053101">Publisher Full Text </a> | <a target=xrefwindow id=d28887e2688 href="http://www.ncbi.nlm.nih.gov/pmc/articles/397380">Free Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d28887e2697 class=n-a></a>Hu J, Liu YF, Wu CF, <i> et al.</i>: Long-term efficacy and safety of <i>all-trans</i> retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. <i>Proc Natl Acad Sci U S A.</i> 2009; <b>106</b>(9): 33427. <a target=xrefwindow id=d28887e2711 href="http://www.ncbi.nlm.nih.gov/pubmed/19225113">PubMed Abstract </a> | <a target=xrefwindow id=d28887e2715 href="http://dx.doi.org/10.1073/pnas.0813280106">Publisher Full Text </a> | <a target=xrefwindow id=d28887e2718 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2651325">Free Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d28887e2728 class=n-a></a>Ravandi F, Estey E, Jones D, <i> et al.</i>: Effective treatment of acute promyelocytic leukemia with all-<i>trans</i>-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. <i>J Clin Oncol.</i> 2009; <b>27</b>(4): 50410. <a target=xrefwindow id=d28887e2742 href="http://www.ncbi.nlm.nih.gov/pubmed/19075265">PubMed Abstract </a> | <a target=xrefwindow id=d28887e2746 href="http://dx.doi.org/10.1200/JCO.2008.18.6130">Publisher Full Text </a> | <a target=xrefwindow id=d28887e2749 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4881307">Free Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d28887e2758 class=n-a></a>Lo-Coco F, Avvisati G, Vignetti M, <i> et al.</i>: Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. <i>N Engl J Med.</i> 2013; <b>369</b>(2): 11121. <a target=xrefwindow id=d28887e2769 href="http://www.ncbi.nlm.nih.gov/pubmed/23841729">PubMed Abstract </a> | <a target=xrefwindow id=d28887e2772 href="http://dx.doi.org/10.1056/NEJMoa1300874">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725797184"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28887e2781 class=n-a></a>Burnett AK, Russell NH, Hills RK, <i> et al.</i>: Arsenic trioxide and all-<i>trans</i> retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. <i>Lancet Oncol.</i> 2015; <b>16</b>(13): 1295305. <a target=xrefwindow id=d28887e2795 href="http://www.ncbi.nlm.nih.gov/pubmed/26384238">PubMed Abstract </a> | <a target=xrefwindow id=d28887e2799 href="http://dx.doi.org/10.1016/S1470-2045(15)00193-X">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725797184">F1000 Recommendation</a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727137606"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28887e2812 class=n-a></a>Abaza Y, Kantarjian H, Garcia-Manero G, <i> et al.</i>: Long-term outcome of acute promyelocytic leukemia treated with all-<i>trans</i>-retinoic acid, arsenic trioxide, and gemtuzumab. <i>Blood.</i> 2017; <b>129</b>(10): 12751283. <a target=xrefwindow id=d28887e2826 href="http://www.ncbi.nlm.nih.gov/pubmed/28003274">PubMed Abstract </a> | <a target=xrefwindow id=d28887e2830 href="http://dx.doi.org/10.1182/blood-2016-09-736686">Publisher Full Text </a> | <a target=xrefwindow id=d28887e2833 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5413297">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727137606">F1000 Recommendation</a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726500402"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28887e2846 class=n-a></a>Platzbecker U, Avvisati G, Cicconi L, <i> et al.</i>: Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. <i>J Clin Oncol.</i> 2017; <b>35</b>(6): 605612. <a target=xrefwindow id=d28887e2857 href="http://www.ncbi.nlm.nih.gov/pubmed/27400939">PubMed Abstract </a> | <a target=xrefwindow id=d28887e2860 href="http://dx.doi.org/10.1200/JCO.2016.67.1982">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726500402">F1000 Recommendation</a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d28887e2873 class=n-a></a>Iland H, Bradstock K, Seymour J, <i> et al.</i>: Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. <i>Haematologica.</i> 2012; <b>97</b>(2): 22734. <a target=xrefwindow id=d28887e2884 href="http://www.ncbi.nlm.nih.gov/pubmed/21993673">PubMed Abstract </a> | <a target=xrefwindow id=d28887e2887 href="http://dx.doi.org/10.3324/haematol.2011.047506">Publisher Full Text </a> | <a target=xrefwindow id=d28887e2891 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3269482">Free Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d28887e2901 class=n-a></a>Yoo ES: Recent advances in the diagnosis and management of childhood acute promyelocytic leukemia. <i>Korean J Pediatr.</i> 2011; <b>54</b>(3): 95105. <a target=xrefwindow id=d28887e2909 href="http://www.ncbi.nlm.nih.gov/pubmed/21738538">PubMed Abstract </a> | <a target=xrefwindow id=d28887e2912 href="http://dx.doi.org/10.3345/kjp.2011.54.3.95">Publisher Full Text </a> | <a target=xrefwindow id=d28887e2915 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3121002">Free Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727234331"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28887e2924 class=n-a></a>Creutzig U, Dworzak MN, Bochennek K, <i> et al.</i>: First experience of the AML-Berlin-Frankfurt-Mnster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-<i>trans</i> retinoid acid. <i>Pediatr Blood Cancer.</i> 2017; <b>64</b>:(8): e26461. <a target=xrefwindow id=d28887e2938 href="http://www.ncbi.nlm.nih.gov/pubmed/28111878">PubMed Abstract </a> | <a target=xrefwindow id=d28887e2942 href="http://dx.doi.org/10.1002/pbc.26461">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727234331">F1000 Recommendation</a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d28887e2955 class=n-a></a>Zhang L, Zhu X, Zou Y, <i> et al.</i>: Effect of arsenic trioxide on the treatment of children with newly diagnosed acute promyelocytic leukemia in China. <i>Int J Hematol.</i> 2011; <b>93</b>(2): 199205. <a target=xrefwindow id=d28887e2966 href="http://www.ncbi.nlm.nih.gov/pubmed/21287409">PubMed Abstract </a> | <a target=xrefwindow id=d28887e2969 href="http://dx.doi.org/10.1007/s12185-011-0768-0">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d28887e2978 class=n-a></a>Cheng Y, Zhang L, Wu J, <i> et al.</i>: Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience. <i>Eur J Haematol.</i> 2013; <b>91</b>(6): 4839. <a target=xrefwindow id=d28887e2989 href="http://www.ncbi.nlm.nih.gov/pubmed/24033687">PubMed Abstract </a> | <a target=xrefwindow id=d28887e2992 href="http://dx.doi.org/10.1111/ejh.12194">Publisher Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d28887e3001 class=n-a></a>Jin B, Hou KZ, Liu YP, <i> et al.</i>: Leukocytosis and retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. <i>Chin Med Sci J.</i> 2006; <b>21</b>(3): 1714. <a target=xrefwindow id=d28887e3012 href="http://www.ncbi.nlm.nih.gov/pubmed/17086739">PubMed Abstract </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d28887e3021 class=n-a></a>Camacho LH, Soignet SL, Chanel S, <i> et al.</i>: Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. <i>J Clin Oncol.</i> 2000; <b>18</b>(13): 26205. <a target=xrefwindow id=d28887e3032 href="http://www.ncbi.nlm.nih.gov/pubmed/10893295">PubMed Abstract </a> | <a target=xrefwindow id=d28887e3035 href="http://dx.doi.org/10.1200/JCO.2000.18.13.2620">Publisher Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d28887e3045 class=n-a></a>Vahdat L, Maslak P, Miller WH Jr, <i> et al.</i>: Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. <i>Blood.</i> 1994; <b>84</b>(11): 38439. <a target=xrefwindow id=d28887e3056 href="http://www.ncbi.nlm.nih.gov/pubmed/7949141">PubMed Abstract </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d28887e3065 class=n-a></a>Tallman MS, Andersen JW, Schiffer CA, <i> et al.</i>: All-<i>trans</i> retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. <i>Blood.</i> 2002; <b>100</b>(13): 4298302. <a target=xrefwindow id=d28887e3079 href="http://www.ncbi.nlm.nih.gov/pubmed/12393590">PubMed Abstract </a> | <a target=xrefwindow id=d28887e3083 href="http://dx.doi.org/10.1182/blood-2002-02-0632">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d28887e3092 class=n-a></a>Ads L, Guerci A, Raffoux E, <i> et al.</i>: Very long-term outcome of acute promyelocytic leukemia after treatment with all-<i>trans</i> retinoic acid and chemotherapy: the European APL Group experience. <i>Blood.</i> 2010; <b>115</b>(9): 16906. <a target=xrefwindow id=d28887e3106 href="http://www.ncbi.nlm.nih.gov/pubmed/20018913">PubMed Abstract </a> | <a target=xrefwindow id=d28887e3110 href="http://dx.doi.org/10.1182/blood-2009-07-233387">Publisher Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d28887e3119 class=n-a></a>Coutre SE, Othus M, Powell B, <i> et al.</i>: Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. <i>Br J Haematol.</i> 2014; <b>165</b>(4): 497503. <a target=xrefwindow id=d28887e3130 href="http://www.ncbi.nlm.nih.gov/pubmed/24528179">PubMed Abstract </a> | <a target=xrefwindow id=d28887e3133 href="http://dx.doi.org/10.1111/bjh.12775">Publisher Full Text </a> | <a target=xrefwindow id=d28887e3137 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4064464">Free Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d28887e3146 class=n-a></a>Shinagawa K, Yanada M, Sakura T, <i> et al.</i>: Tamibarotene as maintenance therapy for acute promyelocytic leukemia: results from a randomized controlled trial. <i>J Clin Oncol.</i> 2014; <b>32</b>(33): 372935. <a target=xrefwindow id=d28887e3157 href="http://www.ncbi.nlm.nih.gov/pubmed/25245439">PubMed Abstract </a> | <a target=xrefwindow id=d28887e3160 href="http://dx.doi.org/10.1200/JCO.2013.53.3570">Publisher Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718144307"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28887e3169 class=n-a></a>Zhu HH, Wu DP, Jin J, <i> et al.</i>: Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. <i>J Clin Oncol.</i> 2013; <b>31</b>(33): 421521. <a target=xrefwindow id=d28887e3180 href="http://www.ncbi.nlm.nih.gov/pubmed/24127444">PubMed Abstract </a> | <a target=xrefwindow id=d28887e3183 href="http://dx.doi.org/10.1200/JCO.2013.48.8312">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718144307">F1000 Recommendation</a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d28887e3197 class=n-a></a>Zhu HH, Huang XJ: Oral arsenic and retinoic acid for non-high-risk acute promyelocytic leukemia. <i>N Engl J Med.</i> 2014; <b>371</b>(23): 223941. <a target=xrefwindow id=d28887e3205 href="http://www.ncbi.nlm.nih.gov/pubmed/25470713">PubMed Abstract </a> | <a target=xrefwindow id=d28887e3208 href="http://dx.doi.org/10.1056/NEJMc1412035">Publisher Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d28887e3217 class=n-a></a>Sanz MA, Lo Coco F, Martn G, <i> et al.</i>: Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. <i>Blood.</i> 2000; <b>96</b>(4): 124753. <a target=xrefwindow id=d28887e3228 href="http://www.ncbi.nlm.nih.gov/pubmed/10942364">PubMed Abstract </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d28887e3237 class=n-a></a>Fenaux P, Le Deley MC, Castaigne S, <i> et al.</i>: Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. <i>Blood.</i> 1993; <b>82</b>(11): 32419. <a target=xrefwindow id=d28887e3248 href="http://www.ncbi.nlm.nih.gov/pubmed/8241496">PubMed Abstract </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/13408973"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28887e3257 class=n-a></a>Avvisati G, Lo-Coco F, Paoloni FP, <i> et al.</i>: AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. <i>Blood.</i> 2011; <b>117</b>(18): 471625. <a target=xrefwindow id=d28887e3268 href="http://www.ncbi.nlm.nih.gov/pubmed/21385856">PubMed Abstract </a> | <a target=xrefwindow id=d28887e3271 href="http://dx.doi.org/10.1182/blood-2010-08-302950">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/13408973">F1000 Recommendation</a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d28887e3284 class=n-a></a>Sanz MA, Montesinos P, Vellenga E, <i> et al.</i>: Risk-adapted treatment of acute promyelocytic leukemia with all-<i>trans</i> retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. <i>Blood.</i> 2008; <b>112</b>(8): 31304. <a target=xrefwindow id=d28887e3298 href="http://www.ncbi.nlm.nih.gov/pubmed/18664623">PubMed Abstract </a> | <a target=xrefwindow id=d28887e3302 href="http://dx.doi.org/10.1182/blood-2008-05-159632">Publisher Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d28887e3311 class=n-a></a>Asou N, Kishimoto Y, Kiyoi H, <i> et al.</i>: A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for <i>PML-RARalpha</i> transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. <i>Blood.</i> 2007; <b>110</b>(1): 5966. <a target=xrefwindow id=d28887e3325 href="http://www.ncbi.nlm.nih.gov/pubmed/17374742">PubMed Abstract </a> | <a target=xrefwindow id=d28887e3329 href="http://dx.doi.org/10.1182/blood-2006-08-043992">Publisher Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 28 Jul 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-1273.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-1273.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> National University Cancer Institute, Singapore, Singapore<br/> <p> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/6-1273/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 28 Jul 2017, 6:1273 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.10736.1">https://doi.org/10.12688/f1000research.10736.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden">  2017 Ng CH and Chng WJ. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=11577 data-id=10736 data-downloads="" data-views="" data-scholar="10.12688/f1000research.10736.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/6-1273/v1/pdf?article_uuid=9c9031e7-dd39-4e81-bd80-00e207367a11" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.10736.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Ng CH and Chng WJ. Recent advances in acute promyelocytic leukaemia [version 1; peer review: 3 approved] <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):1273 (<a href="https://doi.org/10.12688/f1000research.10736.1" target=_blank>https://doi.org/10.12688/f1000research.10736.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=10736 id=mobile-track-article-signin-10736 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/10736?target=/articles/6-1273.html"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=11577 /> <input name=articleId type=hidden value=10736 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Souichi Adachi</strong>, Human Health Science, Kyoto University, Japan </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Ugo Testa</strong>, Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanit, Italy </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Stephen I. Fisher</strong>, Pathology Sciences Medical Group, Sentara Laboratory Services, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 28 Jul 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-1273.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-1273.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=23044-22874></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=23043-22875></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=23045-22873></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=3><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/6-1273/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>28 Jul 17</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Souichi Adachi</strong>, Human Health Science, Kyoto University, Japan </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Ugo Testa</strong>, Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanit, Italy </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Stephen I. Fisher</strong>, Pathology Sciences Medical Group, Sentara Laboratory Services, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/6-1273.html&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/6-1273/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in acute promyelocytic leukaemia".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/6-1273/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/6-1273/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/6-1273/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Ng CH and Chng WJ');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/6-1273/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/6-1273",
            templates : {
                twitter : "Recent advances in acute promyelocytic leukaemia. Ng CH and Chng WJ, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/6-1273/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in acute promyelocytic leukaemia", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in acute promyelocytic leukaemia", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/10736/11577")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "11577");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "22873": 0,
                           "22874": 0,
                           "22875": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "79b647fd-4053-447c-8f92-1a9e3c907742";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-1273.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-1273.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-1273.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/6-1273.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/6-1273.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>